Surgical Animal Model Development
Connecting fundamental research and its application is essential. Protheragen provides state-of-the-art research services tailored to rare cardiovascular diseases and specializes in the creation of surgical animal models which are critical to improving the comprehension and therapy of these challenging disorders. Our company follows ethical principles and regulations that focus on the care and respect of animals used in our models.
Overview of Surgical Animal Models
Surgical animal models of animals are critical in biomedical research since these models simulate human pathologies for further studies on pathophysiology and therapy responses. These models emulating the anatomy and physiology of rare cardiovascular diseases provide an opportunity for researchers to explore the disease's etiology and develop new therapeutic modalities within reasonable limits.
Fig.1 Pulmonary artery banding to create a model of pure RV pressure overload. (Dignam, J. P., et al., 2022)Application of Surgical Animal Models in Rare Cardiovascular Disease Research
Due to their limited frequency of occurrence and multifactorial nature, rare cardiovascular diseases have unique challenges. The surgical animal models help in:
- Identifying Novel Therapeutic Targets
In a controlled environment study of the disease allows researchers to uncover new molecular targets that can be sought after for therapy.
- Understanding Disease Progression
Surgical models assist in elucidating mechanisms directly associated with disease development and progression, aiding in the design of preventive strategies.
- Optimizing Therapeutic Approaches
Intervening testing on the designed models may lead to more effective therapy for individuals afflicted with these rare cardiovascular conditions.
Our Services
Surgical animal models are essential tools for enabling advancements in the understanding of rare cardiovascular diseases and provide a platform for drug safety evaluation and pharmacokinetics research. Our company offers preclinical surgical model development services which serve as a cornerstone for scientists working on novel drugs for rare cardiovascular diseases in any part of the world.
Surgical Animal Models for Rare Cardiovascular Diseases
These are some available surgical animal models for specific rare cardiovascular diseases. Furthermore, we also offer other cardiovascular disease custom surgical model development services. Reach out to us if you require further information.
| Human Disease | Surgical Type | Manipulation Method |
|---|---|---|
| Preeclampsia | Reduced uterine perfusion pressure (RUPP) | Insertion of the silver clips on the aorta and the uterine ovarian arteries. |
| Heart Failure | Transverse aortic constriction surgical procedure (TAC) | Around the transverse aorta, there is a permanent constriction is placed that limits the left ventricular outflow. |
| Hypoplastic Left Heart Syndrome | Left atrial ligation (LAL) | The embryo was carefully rotated into the left lateral position, and a polyamide suture was placed over the left atrial resulting in a volume reduction of the left atrial. |
| Pulmonary Hypertension | Pulmonary artery banding (PAB) | Accomplished by a suture tie or metal clip for mechanical constriction of the pulmonary trunk. |
Surgical Animal Model Development Services
Types of Disease Models
- Rare Arrhythmias
- Rare Cardiomyopathies
- Rare Congenital Heart Diseases
- Rare Vascular Diseases
- Rare Cardiac Tumors
- Other Cardiovascular Diseases
Animal Species Selection
- Mouse Model
- Rat Model
- Rabbit Model
- Zebrafish Model
- Pig Model
- Non-human Primates
- Others
Protheragen is dedicated to assisting the scientific community in combating rare cardiovascular diseases. Our surgical animal model development services are tailored to provide researchers with the resources necessary to achieve breakthroughs in this important area. For further details about any of our services or to talk about your particular research requirements, contact us today!
Reference
- Dignam, Joshua P et al. "Animal models of pulmonary hypertension: Getting to the heart of the problem." British journal of pharmacology 179.5 (2022): 811-837.
For research use only, not for clinical use.